About Cardiff Oncology, Inc.
https://www.cardiffoncology.comCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.
CEO
Mark Erlander
Compensation Summary
(Year 2024)
Option Awards $1,471,762
Total Compensation $1,471,762
Industry Biotechnology
Sector Healthcare
Went public July 27, 2004
Method of going public IPO
Full time employees 32
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-02-20 | Reverse | 1:6 |
| 2018-06-04 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Total 48
Showing Top 3 of 48
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
BLACKROCK, INC.
Shares:3.99M
Value:$11.2M
VANGUARD GROUP INC
Shares:3.59M
Value:$10.08M
BLACKROCK INC.
Shares:2.63M
Value:$7.39M
Summary
% Of Shares Owned 38.69%
Total Number Of Holders 126
Showing Top 3 of 126
Market Cap $213.41 M
52w High $4.99
52w Low $1.90
P/E -3.56
Volume 1.35M
Outstanding Shares 67.32M
About Cardiff Oncology, Inc.
https://www.cardiffoncology.comCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $120K ▼ | $12.09M ▲ | $-11.26M ▲ | -9.38K% ▲ | $-0.17 ▲ | $-10.76M ▲ |
| Q2-2025 | $121K ▲ | $3.32M ▼ | $-13.94M ▼ | -11.52K% ▲ | $-0.21 ▼ | $-14.68M ▼ |
| Q1-2025 | $109K ▼ | $14.49M ▲ | $-13.43M ▼ | -12.32K% ▼ | $-0.2 ▲ | $-14.15M ▼ |
| Q4-2024 | $151K ▼ | $12.72M ▲ | $-11.79M ▲ | -7.81K% ▼ | $-0.25 | $-12.48M ▲ |
| Q3-2024 | $165K | $3.13M | $-11.86M | -7.18K% | $-0.25 | $-12.5M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $60.59M ▼ | $63.78M ▼ | $14.99M ▼ | $48.79M ▼ |
| Q2-2025 | $70.96M ▼ | $75.74M ▼ | $17.13M ▲ | $58.61M ▼ |
| Q1-2025 | $79.89M ▼ | $84.81M ▼ | $13.93M ▼ | $70.88M ▼ |
| Q4-2024 | $91.75M ▲ | $97.19M ▲ | $14.24M ▲ | $82.95M ▲ |
| Q3-2024 | $57.67M | $62.9M | $13.5M | $49.39M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.26M ▲ | $-10.83M ▼ | $10.16M ▲ | $25K ▲ | $-649K ▲ | $-10.85M ▼ |
| Q2-2025 | $-13.94M ▼ | $-8.33M ▲ | $-4.98M ▲ | $0 ▼ | $-13.31M ▲ | $-8.35M ▲ |
| Q1-2025 | $-13.43M ▼ | $-12.79M ▼ | $-14.58M ▼ | $3K ▼ | $-27.38M ▼ | $-12.79M ▼ |
| Q4-2024 | $-11.79M ▲ | $-10.27M ▲ | $4.51M ▲ | $44.19M ▲ | $38.43M ▲ | $-10.27M ▲ |
| Q3-2024 | $-11.86M | $-10.46M | $-9.43M | $7.43M | $-12.46M | $-10.46M |
Revenue by Products
| Product | Q2-2019 | Q3-2019 | Q4-2019 |
|---|---|---|---|
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mark Erlander
Compensation Summary
(Year 2024)
Option Awards $1,471,762
Total Compensation $1,471,762
Industry Biotechnology
Sector Healthcare
Went public July 27, 2004
Method of going public IPO
Full time employees 32
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-02-20 | Reverse | 1:6 |
| 2018-06-04 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Total 48
Showing Top 3 of 48
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
BLACKROCK, INC.
Shares:3.99M
Value:$11.2M
VANGUARD GROUP INC
Shares:3.59M
Value:$10.08M
BLACKROCK INC.
Shares:2.63M
Value:$7.39M
Summary
% Of Shares Owned 38.69%
Total Number Of Holders 126
Showing Top 3 of 126